Clinical Trials for Mesothelioma

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and previously treated advanced mesothelioma or other solid tumors receive oral VT3989, an investigational TEAD inhibitor that blocks palmitoylation and YAP-driven transcription. Combination cohorts evaluate VT3989 with nivolumab/ipilimumab in previously untreated unresectable or metastatic mesothelioma, or with osimertinib in locally advanced or metastatic EGFR-mutant NSCLC.

ClinicalTrials.gov ID: NCT04665206

A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with mesothelin-expressing recurrent or relapsed advanced ovarian, primary peritoneal, or fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma after at least one systemic therapy receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110. This autologous engineered T-cell therapy targets mesothelin through a KIR-based chimeric receptor with DAP12 signaling.

ClinicalTrials.gov ID: NCT05568680

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors or lymphoma, including disease-specific cohorts defined by ARID1A mutation or BAP1 loss, receive oral tulmimetostat, an investigational EZH2/EZH1 inhibitor that disrupts PRC2-mediated gene repression. A metastatic castration-resistant prostate cancer cohort receives tulmimetostat with enzalutamide.

ClinicalTrials.gov ID: NCT04104776

Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously treated diffuse pleural mesothelioma (post platinum/pemetrexed and/or immunotherapy) receive sacituzumab govitecan-hziy, a Trop-2–targeted antibody–drug conjugate delivering SN-38, with imaging-based response assessment by modified RECIST. Key eligibility includes measurable disease, ECOG 0 or KPS ≥70%, adequate organ function, and willingness for biopsies; notable exclusions include significant uncontrolled comorbidities and active uncontrolled viral infections.

ClinicalTrials.gov ID: NCT06477419

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced, metastatic, or recurrent mesothelioma (epithelioid or biphasic with >80% epithelioid), or other solid tumors with high mesothelin expression (≥50% of tumor cells), who have progressed after standard therapies. Treatment involves lymphodepleting chemotherapy followed by a single infusion of autologous CAR T cells (TNhYP218) engineered to target a membrane-proximal epitope of mesothelin, using naive/stem cell memory T cells to potentially enhance efficacy.

ClinicalTrials.gov ID: NCT06885697

Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with unresectable, CD30-positive malignant mesothelioma (any site/histology), previously treated or chemo‑naive, ECOG 0–2. Patients receive brentuximab vedotin IV every 21 days; this anti‑CD30 antibody-drug conjugate delivers MMAE to CD30-expressing cells, aiming for disease control with correlative biomarker analyses.

ClinicalTrials.gov ID: NCT03007030

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with HRD-positive malignant mesothelioma (pleural, peritoneal, or tunica vaginalis) who are platinum-sensitive after prior cisplatin/carboplatin, ECOG 0–1, receive single-agent olaparib. Olaparib is an oral PARP1/2 inhibitor leveraging synthetic lethality in BAP1/HRR-deficient tumors; excludes prior PARP use and platinum-resistant disease.

ClinicalTrials.gov ID: NCT04515836

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease: A Phase I Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For adults (18–<80) with symptomatic, biopsy-proven pleural malignancy including pleural mesothelioma with pleural effusions refractory to available standard therapies and adequate performance status/organ function, this study tests locally manufactured autologous “Fast TILs” (pleural effusion–derived pleural-infiltrating T cells expanded ex vivo to enrich tumor-reactive T cells) given as a one-time intrapleural infusion after outpatient lymphodepleting chemotherapy. Patients then receive short-course low-dose intrapleural IL-2 to support T-cell activation and persistence.

ClinicalTrials.gov ID: NCT07192900

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors: A Phase I Trial (FAST TILS 2)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with symptomatic malignant pleural effusion from pleural mesothelioma or epithelial/mesothelial tumors metastatic to the pleura, refractory to standard therapies and with ECOG 0–1, receive outpatient lymphodepletion followed by intrapleural infusion of autologous pleural infiltrating T cells expanded ex vivo from their pleural fluid. Low-dose intrapleural IL-2 is given after cell infusion to support T-cell activation/persistence; the study primarily assesses manufacturing feasibility and safety with early signals of antitumor activity.

ClinicalTrials.gov ID: NCT07443020

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors after at least one prior therapy are eligible for the currently enrolling dose-escalation cohorts, including patients previously treated with anti–PD-1/PD-L1 therapy. Treatment is oral alintegimod, an investigational LFA-1/VLA-4 integrin agonist, initially alone and then with ipilimumab, followed by nivolumab monotherapy.

ClinicalTrials.gov ID: NCT06362369